Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Envoy Medical, Inc.

CIK 1840877 COCH·Manufacturing · All EDGAR filings ↗

Progression

  1. Auditor change 8-K
  2. Going concern 10-Q +41d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

Envoy Medical, Inc. disclosed substantial doubt about its ability to continue as a going concern

Substantial doubt raised, alleviated by management's plans Substantial doubt about ability to continue as a going concern

Liquidity and Going Concern Since inception, the Company has historically incurred negative operating cash flows and losses from operations as the Company advances the clinical development of its products and the funding process of clinical FDA trials. These matters raise substantial doubt about the Company’s ability to continue as a going concern and although management has developed plans intended to support ongoing operations, such plans do not alleviate the substantial doubt. As of June 30, 2026, the Company has an accumulated deficit of $326,369. On various dates in 2025, the Company…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
going-concern note
Prior filed
2026-05-11
Prior form
10-Q
Prior state
doubt_alleviated
Prior state label
Substantial doubt raised, alleviated by management's plans
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.
Going concern Filing comparison

Envoy Medical, Inc. said management's plans alleviate substantial doubt about going concern

Substantial doubt about ability to continue as a going concern Substantial doubt raised, alleviated by management's plans

Liquidity and Going Concern Since inception, the Company has historically incurred negative operating cash flows and losses from operations as the Company advances the clinical development of its products and the funding process of clinical FDA trials. These matters raise substantial doubt about the Company’s ability to continue as a going concern and although management has developed plans intended to support ongoing operations, such plans do not alleviate the substantial doubt. As of March 31, 2026, the Company has an accumulated deficit of $319,097. From February 2024 to June 2025, the…
Evidence
Blank check
No
Comparable
Yes
Current state
doubt_alleviated
Current state label
Substantial doubt raised, alleviated by management's plans
Direction
eased
Located in
going-concern note
Prior filed
2025-11-10
Prior form
10-Q
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.
Auditor change SEC item code

Envoy Medical, Inc. reported a change in its independent accounting firm

The company dismissed the auditor. Grant Thornton not stated

Evidence
Direction
dismissed
Direction label
The company dismissed the auditor
Item code
4.01
Item title
Changes in Registrant's Certifying Accountant
Predecessor auditor
Grant Thornton
Predecessor tier
national
Severity
normal
Source
SEC 8-K item code
Why
The company's independent registered accounting firm changed.